LANGERHANS CELL HISTIOCYTOSIS (LCH)
Clinical trials for LANGERHANS CELL HISTIOCYTOSIS (LCH) explained in plain language.
Never miss a new study
Get alerted when new LANGERHANS CELL HISTIOCYTOSIS (LCH) trials appear
Sign up with your email to follow new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough blood disorder: Three-Drug combo enters trial
Disease control OngoingThis study is testing whether a combination of three drugs—selinexor, thalidomide, and dexamethasone—can help control Langerhans cell histiocytosis (LCH) in adults whose disease has come back or hasn't responded to previous treatments. It will involve about 40 participants at mul…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Experimental drug trial offers hope for rare blood disease patients
Disease control OngoingThis study is testing whether the chemotherapy drug lenalidomide can help control three rare disorders where the body makes too many immune cells. Researchers are enrolling 12 adults with Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma who need syst…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study aims to understand the genetic causes of several rare blood diseases by analyzing patients' DNA. Researchers will look for specific genetic changes that might be targeted by existing or future treatments. The study involves collecting blood or tissue samples from 135 p…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC